Holen Sie sich die Stockscreener-App
14.40
1.77%
-0.26
Vorhandelsmarkt:
14.32
-0.08
-0.56%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$14.66
Offen:
$14.65
24-Stunden-Volumen:
2.82M
Relative Volume:
0.98
Marktkapitalisierung:
$2.87B
Einnahmen:
$3.90B
Nettoeinkommen (Verlust:
$-413.00M
KGV:
-6.9565
EPS:
-2.07
Netto-Cashflow:
$365.00M
1W Leistung:
+3.90%
1M Leistung:
-10.17%
6M Leistung:
-23.49%
1J Leistung:
-43.11%
1-Tages-Spanne:
$14.38
$14.66
1-Wochen-Bereich:
$13.85
$14.71
52-Wochen-Spanne:
$12.16
$27.48
Dentsply Sirona Inc Stock (XRAY) Company Profile
Firmenname
Dentsply Sirona Inc
Sektor
Telefon
844-546-3722
Adresse
13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE, NC
Vergleichen Sie XRAY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XRAY
Dentsply Sirona Inc
|
14.40 | 2.76B | 3.90B | -413.00M | 365.00M | -2.07 |
|
ISRG
Intuitive Surgical Inc
|
468.44 | 172.53B | 9.15B | 2.63B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
194.65 | 55.89B | 21.39B | 1.61B | 2.55B | 5.56 |
|
ALC
Alcon Inc
|
80.77 | 43.59B | 9.93B | 1.12B | 1.43B | 2.26 |
|
RMD
Resmed Inc
|
285.77 | 41.89B | 5.15B | 1.40B | 1.65B | 9.51 |
|
WST
West Pharmaceutical Services Inc
|
247.07 | 17.48B | 2.96B | 487.70M | 344.00M | 6.68 |
Dentsply Sirona Inc Stock (XRAY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-15 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-13 | Herabstufung | Needham | Buy → Hold |
| 2025-02-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2025-01-23 | Herabstufung | Jefferies | Buy → Hold |
| 2025-01-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-12-04 | Eingeleitet | Mizuho | Neutral |
| 2024-11-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-10-25 | Bestätigt | Needham | Buy |
| 2024-08-20 | Bestätigt | Needham | Buy |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-16 | Eingeleitet | Needham | Buy |
| 2023-11-10 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-01-12 | Hochstufung | William Blair | Underperform → Mkt Perform |
| 2022-08-05 | Herabstufung | William Blair | Mkt Perform → Underperform |
| 2022-06-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-04-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-04-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2022-04-19 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-04-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-01-31 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-10-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-08-09 | Bestätigt | H.C. Wainwright | Neutral |
| 2021-08-06 | Bestätigt | Barrington Research | Outperform |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-02 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2021-03-02 | Bestätigt | H.C. Wainwright | Neutral |
| 2021-01-05 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-12-18 | Herabstufung | Stifel | Buy → Hold |
| 2020-11-17 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-10-22 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-08-10 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-06-16 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-15 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-05-27 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-05-11 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-04-24 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-04-08 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2020-04-07 | Herabstufung | Goldman | Buy → Neutral |
| 2020-04-02 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-03-03 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-02-19 | Bestätigt | Stifel | Buy |
| 2019-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-08-02 | Hochstufung | Wellington Shields | Hold → Gradually Accumulate |
| 2019-07-26 | Eingeleitet | Evercore ISI | In-line |
| 2019-07-09 | Bestätigt | H.C. Wainwright | Neutral |
| 2019-05-30 | Eingeleitet | Wolfe Research | Peer Perform |
Alle ansehen
Dentsply Sirona Inc Aktie (XRAY) Neueste Nachrichten
Is DENTSPLY SIRONA Inc. Forming a Consolidation BaseJuly 2025 Snapshot & Free Weekly Chart Analysis and Trade Guides - classian.co.kr
Dentsply Sirona: Turnaround Potential And Digital Workflows (NASDAQ:XRAY) - Seeking Alpha
SureSmile clear aligners—a proven system for predictably treating malocclusion - Dental Tribune US
Dentures Market Future Business Opportunities 2025-2032 | Dentsply Sirona Inc., Ivoclar Vivadent Ag, GC America Inc - openPR.com
Dentsply Sirona shares rise 2.53% premarket after announcing the availability of CEREC Tessera®. - AInvest
CEOs linked to $3M+ home purchases in Charlotte - The Business Journals
Dental CAD-CAM Market Forecast and Company Analysis Report 2025-2029, with 3Shape, Align Technology, Carestream Dental, Dentsply Sirona, Jensen Dental, Schutz Dental, and Yenadent - Yahoo Finance
Digital Dentistry Solutions Market 9.90% CAGR Analysis with - openPR.com
Will DENTSPLY SIRONA Inc. announce a stock splitJuly 2025 Volume & High Conviction Investment Ideas - thegnnews.com
Can DENTSPLY SIRONA Inc. disrupt its industryBuy Signal & Risk Managed Investment Strategies - thegnnews.com
Dentsply Sirona Settled $84M Over Anti-Competitive Practices – How to Claim Your Payout - TradingView
Dentsply Sirona : Sustainability Report 2024 Fifth year of continued progress, with several goals reached ahead of time - MarketScreener
Dental Implants and Prosthetics Company Evaluation Report 2025 | Institut Straumann, Envista, and Dentsply Sirona Lead with Innovation and Expansive Portfolios - Yahoo Finance
Dental Burs Market 2025 | Size, Trends, Innovations & Global - openPR.com
Mizuho lowers Dentsply Sirona stock price target on margin concerns By Investing.com - Investing.com Canada
Stocks Surge Amid Fed Interest Rate Speculation: Tandem Diabetes, Enovis, Dentsply Sirona, Centene, and Molina Healthcare Among Winners - AInvest
Tandem Diabetes, Enovis, Dentsply Sirona, Centene, and Molina Healthcare Shares Are Soaring, What You Need To Know - uk.finance.yahoo.com
Tandem Diabetes, Enovis, Dentsply Sirona, Centene, and Molina Healthcare Shares Are Soaring, What You Need To Know | FinancialContent - FinancialContent
Analysts’ Top Healthcare Picks: DENTSPLY SIRONA (XRAY), Replimune Group (REPL) - The Globe and Mail
Healthcare Analysts Offer Insights on Trevi Therapeutics, DENTSPLY SIRONA, and Arrowhead Pharmaceuticals. - AInvest
DENTSPLY SIRONA, Replimune Group, and Enovis Analysts Maintain Neutral Ratings - AInvest
UFP Technologies, Inspire Medical Systems, Globus Medical, Neogen, and Dentsply Sirona stocks soar on positive inflation data, Fed rate cut hopes. - AInvest
Inspire Medical Systems, UFP Technologies, Globus Medical, Neogen, and Dentsply Sirona Shares Skyrocket, What You Need To Know - Yahoo Finance
Dentsply Sirona Requests to Dismiss Class Action Filed by Investors - TradingView
Intraoral radiography market to hit US$ 2.7 billion by 2031 | Top - openPR.com
Understanding The Growth Of The Clear Aligners Market By 2035 - PharmiWeb.com
International Markets and Dentsply (XRAY): A Deep Dive for Investors - Yahoo Finance
DENTSPLY SIRONA outlines $80M annualized tariff headwind, maintains full-year outlook as new CEO signals accelerated transformation - MSN
DENTSPLY SIRONA Second Quarter 2025 Earnings: EPS Misses Expectations - Yahoo Finance
Dentsply Sirona Reports Q2 Earnings Below Expectations, Maintains FY25 Outlook - AInvest
Dentsply Sirona (XRAY) Q2 Sales Drop 5% - AOL.com
Dentsply Sirona shares fall 1.59% intraday after UBS trims price target to $24. - AInvest
Dentsply Sirona shares fall 4.16% intraday as UBS lowers price target to $24. - AInvest
Why Dentsply International (XRAY) is a Top Growth Stock for the Long-Term - Yahoo Finance
UBS Trims Dentsply Sirona Price Target to $24 From $25, Maintains Buy Rating - MarketScreener
Dentsply Sirona price target lowered to $24 from $25 at UBS - TipRanks
Dentsply Sirona Reports Q2 2025 Financial Results - TipRanks
Dentsply Sirona Maintains Outlook Despite Sales Decline - AOL.com
DENTSPLY's Q2 2025 Earnings Call: Unpacking Contradictions in Tariffs, Orthodontics, and Customer Support - AInvest
Jefferies lowers Dentsply Sirona stock price target to $15 on tariff concerns - Investing.com Canada
Dentsply Sirona shares rise 1.66% after-hours following Q2 earnings call with adjusted earnings rise. - AInvest
DENTSPLY SIRONA: Hold Rating Maintained Amidst Mixed Performance and Promising Margin Improvements - TipRanks
Dentsply Sirona’s (NASDAQ:XRAY) Q2 Earnings Results: Revenue In Line With Expectations - Yahoo Finance
DENTSPLY SIRONA Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings call transcript: Dentsply Sirona Q2 2025 sees earnings beat, stock rises - Investing.com
DENTSPLY SIRONA Q2 2025 Earnings Call Transcript - MarketBeat
XRAY Stock Rises on Q2 Earnings & Revenues Beat, Adjusted Margins Up - Yahoo Finance
Deadline to Claim Your Payout from the $84M Dentsply Sirona Settlement Is in 2 Months - TradingView
Transcript : DENTSPLY SIRONA Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Dentsply (XRAY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
DENTSPLY SIRONA Inc. SEC 10-Q Report - TradingView
Finanzdaten der Dentsply Sirona Inc-Aktie (XRAY)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.08%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):